IRTC 📈 iRhythm Technologies - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4500561067
IRTC: ECG, Monitoring, Patch, System, Arrhythmia, Detection
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California. Web URL: https://www.irhythmtech.com
Additional Sources for IRTC Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IRTC Stock Overview
Market Cap in USD | 2,828m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2016-10-20 |
IRTC Stock Ratings
Growth 5y | -9.57% |
Fundamental | -52.5% |
Dividend | - |
Rel. Strength Industry | -378 |
Analysts | 4.46/5 |
Fair Price Momentum | 86.57 USD |
Fair Price DCF | - |
IRTC Dividends
No Dividends PaidIRTC Growth Ratios
Growth Correlation 3m | 79.3% |
Growth Correlation 12m | -81.4% |
Growth Correlation 5y | -24.9% |
CAGR 5y | 5.93% |
CAGR/Mean DD 5y | 0.12 |
Sharpe Ratio 12m | -0.10 |
Alpha | -50.01 |
Beta | 1.39 |
Volatility | 64.51% |
Current Volume | 518.1k |
Average Volume 20d | 349.9k |
What is the price of IRTC stocks?
As of December 21, 2024, the stock is trading at USD 90.39 with a total of 518,055 shares traded.
Over the past week, the price has changed by +4.58%, over one month by +22.58%, over three months by +29.13% and over the past year by -14.31%.
As of December 21, 2024, the stock is trading at USD 90.39 with a total of 518,055 shares traded.
Over the past week, the price has changed by +4.58%, over one month by +22.58%, over three months by +29.13% and over the past year by -14.31%.
Is iRhythm Technologies a good stock to buy?
No, based on ValueRay Fundamental Analyses, iRhythm Technologies (NASDAQ:IRTC) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -52.48 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IRTC as of December 2024 is 86.57. This means that IRTC is currently overvalued and has a potential downside of -4.23%.
No, based on ValueRay Fundamental Analyses, iRhythm Technologies (NASDAQ:IRTC) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -52.48 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IRTC as of December 2024 is 86.57. This means that IRTC is currently overvalued and has a potential downside of -4.23%.
Is IRTC a buy, sell or hold?
iRhythm Technologies has received a consensus analysts rating of 4.46. Therefor, it is recommend to buy IRTC.
iRhythm Technologies has received a consensus analysts rating of 4.46. Therefor, it is recommend to buy IRTC.
- Strong Buy: 8
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecast for IRTC stock price target?
According to ValueRays Forecast Model, IRTC iRhythm Technologies will be worth about 96 in December 2025. The stock is currently trading at 90.39. This means that the stock has a potential upside of +6.22%.
According to ValueRays Forecast Model, IRTC iRhythm Technologies will be worth about 96 in December 2025. The stock is currently trading at 90.39. This means that the stock has a potential upside of +6.22%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 100.9 | 11.6% |
Analysts Target Price | 126.7 | 40.1% |
ValueRay Target Price | 96 | 6.2% |